Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05373719

Observational Study in Patients With Cyclin-dependent Kinase-like 5 Deficiency Disorder

Observational, noninterventional, 3-year study to examine the presence of detectable differences in neurocognitive, developmental, motor, neurophysiologic, and quality of life measures over time in patients with cyclin-dependent kinase-like 5 deficiency disorder.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

Up to 55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Alberta Children's Hospital, Pediatric Epilepsy and Child Neurology, Calgary, Canada

Loading trial locations.

About this study

This is an observational study to examine the presence of detectable differences in neurocognitive, developmental, motor, neurophysiologic, and quality of life measures over time in approximately up to 100 patients aged birth to 55 years and diagnosed with cyclin-dependent kinase-like 5 deficiency disorder. Operational performance across age groups and languages will be assessed throughout the study, and Baseline cohort characteristics will be assessed throughout enrollment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Documented diagnosis of Cyclin-dependent Kinase-like 5 (CDKL5) deficiency disorder with pathogenic or likely pathogenic of CDKL5 variants
  • Ages newborn to 55 years old
  • Parent/Caregiver who is willing and capable of providing written informed consent
  • Parent/caregiver lives with or has daily contact with study participant and able to provide consistent information across the study

Exclusion criteria

  • Any clinically significant neurocognitive deficit not attributable to Cyclin-dependent Kinase-like 5 (CDKL5) deficiency disorder or a secondary cause that may, in the opinion of the investigator, confound interpretation of study results (e.g., extreme prematurity, other genetic variants, unclassified CDKL5 variant, abnormal brain imaging, imaging and/or injury not otherwise attributable to CDD).
  • Any condition that, in the opinion of the investigator, would put the patient at undue risk or make it unsafe for the patient to participate
  • Any condition which would make the individual or the caregiver, in the opinion of the investigator, unsuitable for the study

Treatment and study plan

No intervention; observational

Other

No intervention; observational

Primary outcomes

  1. Bayley Scale of Infant and Toddler Development, Fourth Edition (BSID-4)

    Time frame: Baseline

    Suitability of this cognition and global development scale in CDD will be assessed based on the number of tests completed, ceiling/floor effect and variance estimate.

  2. Vineland 3

    Time frame: Baseline

    Suitability of this adaptive behavior scale in CDD will be assessed based on the number of tests completed, ceiling/floor effect and variance estimate.

  3. Gross Motor Function Measure (GMFM)

    Time frame: Baseline

    Suitability of this motor function scale in CDD will be assessed based on the number of tests completed, ceiling/floor effect and variance estimate.

  4. Sleep Disturbance Scale for Children (SDSC)

    Time frame: Baseline

    Suitability of this sleep quality scale in CDD will be assessed based on the number of tests completed, ceiling/floor effect and variance estimate.

Secondary outcomes

  1. Changes in test results over time.

    Time frame: 36 months

  2. Correlations between age and test results.

    Time frame: 36 months

  3. Correlations between gender and test results.

    Time frame: 36 months

  4. Correlation between test results and seizure severity.

    Time frame: 36 months

Sponsors and collaborators

Lead sponsor

Loulou Foundation

Other

Registry information

Official study title

Endpoint Enabling Study of Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD)

Acronym: CANDID

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
May 13, 2022
Registry last updated
Mar 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.